CN105125533A - Medicine for treating rhinitis and application thereof - Google Patents
Medicine for treating rhinitis and application thereof Download PDFInfo
- Publication number
- CN105125533A CN105125533A CN201510507088.0A CN201510507088A CN105125533A CN 105125533 A CN105125533 A CN 105125533A CN 201510507088 A CN201510507088 A CN 201510507088A CN 105125533 A CN105125533 A CN 105125533A
- Authority
- CN
- China
- Prior art keywords
- medicine
- rhinitis
- hydrangenone
- compound
- treating rhinitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention belongs to the field of medicines and particularly relates to a medicine for treating rhinitis. The medicine is composed of a compound Hydrangenone and auxiliary materials, has an obvious curative effect and is disclosed for the first time. Since a skeleton type belongs to brand-new skeleton types and in addition, the medicine has high activity for treating rhinitis, has the characteristic of prominent substantiality, and meanwhile is used for treating rhinitis, a significant progress is realized obviously.
Description
Technical field
The present invention relates to the novelty teabag of compound H ydrangenone, particularly relate to the application of Hydrangenone in preparation treatment rhinitis medicine.
Background technology
Rhinitis is common clinical and frequently-occurring disease, and the generation of rhinitis is main relevant with anaphylaxis, belongs to the category of immune inflammation.At present, treatment rhinitis mainly adopt the antihistamine drug such as teldane or the Claritin such as tranilast, ketotifen, these medicines to the chronicity of rhinitis and recurrent exerbation curative effect poor or invalid.Therefore, definite ingredients, quality controllable and safely and efficiently micromolecular compound in development treatment of rhinitis medicine, there is potential value.
The compound H ydrangenone that the present invention relates to be one within 2012, deliver (M.MoridiFarimani, *,
etal., Hydrangenone, aNewIsoprenoidwithanUnprecedentedSkeletonfromSalviahydra ngea.ORGANICLETTERS, 2012,14 (1): 166 – 169.) noval chemical compound, this compound has brand-new framework types, only can suppress plasmodium (M.MoridiFarimani, *
etal., Hydrangenone, aNewIsoprenoidwithanUnprecedentedSkeletonfromSalviahydra ngea.ORGANICLETTERS, 2012,14 (1): 166 – 169.), the purposes of the Hydrangenone that the present invention relates in preparation treatment rhinitis medicine belongs to first public.
Summary of the invention
The object of the present invention is to provide a kind of anti-rhinitis medicament thing and application thereof.
One treats rhinitis medicine, is made up of compound H ydrangenone and adjuvant, and described compound H ydrangenone structure is as shown in formula I:
Described treatment rhinitis medicine, adjuvant is dextrin or starch.
The application of described treatment rhinitis medicine in preparation treatment rhinitis medicine.
Compound H ydrangenone10,20mg/kg oral administration, raise inhibited to scratch nose, sneeze reaction and nasal cavity vascular permeability of rat caused by antigen (ovalbumin) and histamine, therefore, can be used for the medicine preparing treatment rhinitis.The purposes of Hydrangenone in preparation treatment rhinitis medicine belongs to first public, because framework types belongs to brand-new framework types, and its treatment rhinitis is active strong, possess outstanding substantive distinguishing features, the control simultaneously for rhinitis obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Detailed description of the invention
The preparation method of compound H ydrangenone involved in the present invention see document (M.MoridiFarimani, *,
etal., Hydrangenone, aNewIsoprenoidwithanUnprecedentedSkeletonfromSalviahydra ngea.ORGANICLETTERS, 2012,14 (1): 166 – 169.)
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not by any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H ydrangenone tablet involved in the present invention:
Get 5 g of compound Hydrangenone, add 195 grams, dextrin, mixing, Conventional compression makes 1000.
Embodiment 2: the preparation of compound H ydrangenone capsule involved in the present invention:
Get 5 g of compound Hydrangenone, add starch 195 grams, mixing, encapsulatedly makes 1000.
Its pharmaceutically active is further illustrated below by pharmacodynamic experiment.
Experimental example 1, Hydrangenone of the present invention cause the impact of rat allergic rhinitis on ovalbumin
Male SD rat, body weight 180 ~ 220g, lumbar injection ovalbumin 1mg and gel aluminum hydroxide 10mg, inject 1 time next day of thereafter, totally 7 times.Began from the 14th day, every day instills 1mg/ml ovalbumin normal saline solution 10ul at rat both sides nasal cavity, totally 7 times.Last is observed rat sneeze in 30 minutes at once and is wiped the number of times of nose after instiling, trial drug instils in ovalbumin last and orally to give (by the preparation of above-described embodiment 1 method) for first 1 hour.
Table 1 Hydrangenone of the present invention causes the impact (x ± SD) of rat allergic rhinitis to ovalbumin
Compare with matched group, * * P<0.01*P<0.05
From table 1, Hydrangenone (10,20mg/kg) obviously suppresses the sneeze of allergic rhinitis rat caused by ovalbumin and nose reaction of scratching.Teldane 10mg/kg also presents significant inhibitory action.
Experimental example 2, Hydrangenone of the present invention are on the impact of the rat rhinitis that histamine causes
Male SD rat, body weight 180 ~ 220g, orally to give after trial drug 1 hour, and both sides nasal cavity instillation 1M histamine normal saline solution 10ul, observes the number of times of rat sneeze and wiping nose in 30 minutes.
Table 2 Hydrangenone of the present invention causes the impact (x ± SD) of rat rhinitis to histamine
Compare with matched group, * * P<0.01*P<0.05
From table 2, Hydrangenone of the present invention (10,20mg/kg) obviously reduces the sneeze number of times of rhinitis rat caused by histamine, to nose reaction of scratching in suppression trend.Teldane 10mg/kg is then in significant inhibitory action.
Conclusion: Hydrangenone oral administration, inhibited to scratch nose, sneeze reaction of rat caused by antigen (ovalbumin) and histamine, therefore, can be used for the medicine preparing treatment rhinitis.
Claims (3)
1. treat a rhinitis medicine, it is characterized in that, be made up of compound H ydrangenone and adjuvant, described compound H ydrangenone structure is as shown in formula I:
Formula I.
2. treat rhinitis medicine as claimed in claim 1, it is characterized in that, adjuvant is dextrin or starch.
3. treat the application of rhinitis medicine in treatment rhinitis medicine as claimed in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510507088.0A CN105125533A (en) | 2015-08-18 | 2015-08-18 | Medicine for treating rhinitis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510507088.0A CN105125533A (en) | 2015-08-18 | 2015-08-18 | Medicine for treating rhinitis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105125533A true CN105125533A (en) | 2015-12-09 |
Family
ID=54711357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510507088.0A Pending CN105125533A (en) | 2015-08-18 | 2015-08-18 | Medicine for treating rhinitis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105125533A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102655745A (en) * | 2009-11-12 | 2012-09-05 | 西格纳姆生物科学公司 | Use of anti-bacterial agents for the treatment of epithelial-related conditions |
-
2015
- 2015-08-18 CN CN201510507088.0A patent/CN105125533A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102655745A (en) * | 2009-11-12 | 2012-09-05 | 西格纳姆生物科学公司 | Use of anti-bacterial agents for the treatment of epithelial-related conditions |
Non-Patent Citations (1)
| Title |
|---|
| M.MORIDI FARIMANI,ET AL.: "Hydrangenone, a New Isoprenoid with an Unprecedented Skeleton from Salvia hydrangea", 《ORGANIC LETTERS》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103585150B (en) | Use of Nitrosporeusines A in drugs for treating rhinitis | |
| CN105362274A (en) | Application of biscarpamontamine A in preparation of rhinitis pharmaceuticals | |
| CN103494826B (en) | The application of Phyllanthoid A in preparation treatment rhinitis medicine | |
| CN105125533A (en) | Medicine for treating rhinitis and application thereof | |
| CN105287545A (en) | Applications of Strynuxlines A in preparation of rhinitis treatment drugs | |
| CN102872034B (en) | Application of Gypensapogenin B in medicaments for treating rhinitis | |
| CN105456246A (en) | Application of Lathyranone A in preparation of drug for treating rhinitis | |
| CN106551936A (en) | One kind treats rhinitis medicine and its application | |
| CN103463007A (en) | Application of racemosins A in preparation of medicine treating rhinitis | |
| CN105287495A (en) | Application of Sphenostylisins C in preparation of drugs used for treating rhinitis | |
| CN103330712A (en) | Application of Myriberine A in preparation of a medicine for treating rhinitis | |
| CN103751170B (en) | The application of Trigoxyphin K in treatment rhinitis medicine | |
| CN103462999A (en) | Application of Neonectrolide A in preparing medicament for treating rhinitis | |
| CN106491617A (en) | Applications of the Friedolanostanes in treatment rhinitis medicine is prepared | |
| CN103393699B (en) | The application of Chukrasone A in preparation treatment rhinitis medicine | |
| CN103372006B (en) | The application of Chukrasone B in preparation treatment rhinitis medicine | |
| CN106389404A (en) | Applications of Linderolide H in preparing medicines for treating rhinitis | |
| CN103585152A (en) | Application of Caesanines D in medicament for treating rhinitis | |
| CN105147656A (en) | Application of chlorogenic acid to preparing medicine for treating allergic rhinitis | |
| CN103638007A (en) | Application of Hippolachnin A in medicine for treatment of rhinitis | |
| CN107865846A (en) | Isovitexin is preparing the application in treating rhinitis medicine | |
| CN101155581A (en) | Medicament and treatment for herpes simplex | |
| CN102988390B (en) | Application of Houttuynoid C for preparing medicine for treating rhinitis | |
| CN102988393B (en) | Application of Houttuynoid B for preparing medicine for treating rhinitis | |
| CN107865862A (en) | Apigenin is preparing the application in treating rhinitis medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151209 |